Sun, Apr 20, 2014, 9:03 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rtfa50 rtfa50 Jun 16, 2005 1:07 PM Flag

    what a SWAGN!

    Most likely the reason for todays runup,
    but remember VRTX has only finished Phase 1
    so a buy out would not be at a premium.

    While Pfizer is paying a hefty premium for the products, the price will be worth it if both drugs get approved. Both are now under review by U.S. regulators, having completed all three phases of clinical trials needed for approval.

    Pharmaceutical companies must typically pay more for products from biotechnology companies that have completed or are in Phase III clinical trials than for those that are in earlier stages of development, as the risk of failure is less.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • <<Most likely the reason for todays runup,
      but remember VRTX has only finished Phase 1
      so a buy out would not be at a premium.>>

      Probably true and lets remember that Pahse 2 is the hardest phase to pass.

    • <<Most likely the reason for todays runup,
      but remember VRTX has only finished Phase 1
      so a buy out would not be at a premium.>>
      --------------------------------------
      I personally do not want a buy out even at a premium. I did not hold and kept buying more VRTX hoping only for a premium over the present prices.

      As far as I am concerned the upside potential is enormous if one of the compounds in the pipeline make it to the market.

 
VRTX
64.17-0.22(-0.34%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.